• Investors may be wondering if Bristol-Myers Squibb at around US$59 a share still offers value, or if most of the opportunity is already priced in.
• The stock has returned 0.1% over the past week, 2.8% over the past month, 10.4% year to date and 27.3% over the last year, which naturally raises questions about what is currently baked into expectations.
• Recent attention on large pharmaceutical names, including Bristol-Myers Squibb, has centered on their pipelines, patent cycles and the role of big pharma in healthcare. These factors can influence how investors think about future cash flows and risk, and help explain why moves in the share price can be tied to news on drug approvals, regulatory actions or portfolio reshaping rather than just broad market swings.
• Bristol-Myers Squibb currently has a valuation score of 4/6. The rest of this article will break that down across different valuation methods and then point to a more holistic way to judge value at the end.

Approach 1: Bristol-Myers Squibb Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future cash flows and then discounting those back to today’s value.

For Bristol-Myers Squibb, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $12.9b. Analyst inputs and subsequent extrapolations point to projected free cash flow of $11.4b in 2030, with interim years such as 2026 and 2027 modeled at $15.1b and $14.6b respectively, all in dollars and then discounted back to today.

On this basis, the estimated intrinsic value comes out at roughly $121.81 per share, compared with the recent share price around $59. The model therefore indicates that Bristol-Myers Squibb trades at an implied 51.5% discount to this DCF estimate, which suggests potential upside if these cash flow assumptions hold.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Bristol-Myers Squibb is undervalued by 51.5%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.

Approach 2: Bristol-Myers Squibb Price vs Earnings

For profitable companies, the P/E ratio is a helpful way to gauge how much you are paying for each dollar of current earnings, which tends to be easier to interpret than sales or book value alone.

What counts as a “normal” P/E ratio often reflects the market’s view on two things: how quickly earnings might grow and how risky those earnings are. Higher expected growth and lower perceived risk can support a higher P/E, while slower growth or higher risk usually lines up with a lower multiple.

Bristol-Myers Squibb currently trades on a P/E of about 17.1x. This sits above the Pharmaceuticals industry average of 16.1x and below the peer group average of 19.8x. Simply Wall St’s “Fair Ratio” for Bristol-Myers Squibb is 21.1x, which is a proprietary estimate of what the P/E could be based on factors like earnings growth, industry, profit margins, market cap and risk profile.

This Fair Ratio goes further than a simple peer or industry comparison because it adjusts for company specific traits rather than assuming all large pharma names deserve the same multiple. With the current 17.1x P/E sitting below the 21.1x Fair Ratio, the shares screen as undervalued on this earnings based approach.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Bristol-Myers Squibb Narrative

Earlier it was mentioned that there is an even better way to understand valuation, and on Simply Wall St that means using Narratives. In a Narrative you set out your story for Bristol-Myers Squibb, link that story to a forecast for revenue, earnings and margins, and then see what fair value drops out and how it compares with the current price around US$59. All of this happens inside the Community page where Narratives are hosted and updated as new information like earnings or drug news comes in.

One investor might build a Bristol-Myers Squibb Narrative that leans closer to the higher fair value markers around US$65 to US$75 per share, tying this to views that the growth portfolio, cost savings and late stage pipeline can support earnings and justify a higher P/E or DCF outcome. Another investor might anchor on the lower end near US$45.67 per share if they focus more on patent cliffs, revenue pressure and a lower multiple. By comparing these different Narratives side by side you can quickly see which story and fair value range best matches your own view before deciding how the stock fits into your plan.

For Bristol-Myers Squibb, we will make it really easy for you with previews of two leading Bristol-Myers Squibb Narratives:

Fair value used in this bullish Narrative: US$65.00 per share.

Implied discount to that fair value at the recent US$59.02 share price: about 9.2%.

Revenue growth assumption in this Narrative: 2.43%.

• Sees 2024 as a foundation year with US$48.3b of total revenue and a 17% increase in growth portfolio revenue to US$22.6b, while acknowledging GAAP loss per share of US$4.41 and lower non GAAP EPS of US$1.15.
• Points to approvals such as Opdivo Qvantig and the launch of Cobenfy, together with a US$2b cost saving plan by 2027, as key ingredients that could support earnings power over time.
• Blends external fair value work around US$66 per share with P/E and DCF cross checks that cluster in the low to mid US$60s to arrive at a fair value anchor of about US$65.

Fair value used in this bearish Narrative: US$45.67 per share.

Implied premium to that fair value at the recent US$59.02 share price: about 29.3%.

Revenue growth assumption in this Narrative: 8.08% annual revenue decline.

• Frames loss of exclusivity for Eliquis, Opdivo and Revlimid, together with pricing pressure and higher R&D and regulatory costs, as key headwinds that could weigh on revenue and margins.
• Builds a scenario where revenue trends at an 8.08% annual decline over the next 3 years, margins rise to 21.6% and earnings reach US$8.1b by 2029, valued on a future P/E of 14.1x with a 6.98% discount rate.
• Translates the more cautious analyst assumptions into a fair value of US$45.67, which sits well below both the current share price around US$59.02 and the wider analyst target range that runs from US$40.00 to US$75.00.

Putting these side by side gives you a clear range for Bristol-Myers Squibb, from a bullish anchor around US$65 per share to a bearish anchor near US$45.67, and you can then decide which story feels closer to your own expectations for the business.

To go deeper into these storylines and the numbers behind them, take a look at the full set of community views on Bristol-Myers Squibb including both bullish and bearish Narratives, and see where your own assessment lands between them, then use tools like watchlists and valuation models to track how the picture evolves over time.

Do you think there's more to the story for Bristol-Myers Squibb? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.